Nadroparin (Ca)

Drug #938

Nadroparin (Ca) is a low molecular weight heparin with anti-coagulant properties.Nadroparin (Ca) is used in the treatment and prophylaxis of venous thrombo-embolism and to prevent clotting during extracorporeal circulation.

← Previous drug Next drug →

Primary Characteristics

It is of Semi Synthetic origin and belongs to Sulphopyranosuronic acid.

It is classified in Low Molecular Weight Heparin pharmacological group.

Molecular Weight: 3600 · Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Nadroparin (Ca).

Pharmacokinetics

Elimination: plasma half-life is 3.5 hrs.

Indications

Nadroparin (Ca) is primarily indicated in conditions like Prophylaxis of thrombosis, Pulmonary embolism, Thromboembolism.

Nadroparin (Ca) is also indicated for secondary conditions like Unstable angina.

Contraindications

Nadroparin (Ca) is contraindicated in conditions like Diabetic retinopathy, Severe uncontrolled hypertension, Hypersensitivity to any component of product.

Dosage

Nadroparin (Ca)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
85 units	85 units	Every 12h	S/C	For angina & Treatment of thromboembolism For angina 6 days thromboembolism 10 days
2850 units	2850 units	Every 12h	S/C	For 7 days. For haediallysis & for prophylaxis of venous thromboembolism
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended for this age group
Neonatal Dosage (3kg)
No data.

Drug Interactions

5 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Nadroparin (Ca) are Hemorrhage .

Nadroparin (Ca) is known to cause more or less tolerable side effects which are usually transient. These include Allergic reactions, Bleeding , Hypoaldosteronism, Injection site hematoma, Pain at injection site, Rashes , Thrombocytopenia.

Warnings / Precautions

Patients with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) are at risk of spinal or epidural hematoma and subsequent paralysis. Patient should be closely monitored for sighns or symptoms of bleeding.Should be use with caution in patients with severe hepatic or renal disease. Safety and efficacy in pediatric patients have not been established. Should not be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.

Interference in Pathology

Nadroparin (Ca) may interfere in the diagnosis of Elevation in ALT or AST.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

9500 IU

Storage Conditions

Nadroparin (Ca) should be stored Inj.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators

Manufacturers

Manufacturers of Nadroparin (Ca) in Pakistan:

GSK